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toms. METHODS: Randomized controlled trials (RCT) of adali-
mumab, etanercept and inﬂiximab involving patients with
PsA were searched in MEDLINE by Cochrane Highly Sensitive
Search Strategy. The quality of selected studies was measured
using the Jadad-score. Two clinical outcomes were analyzed:
the rate of patients achieving at least 20% improvement by the
American College of Rheumatology criteria (ACR20) and the
Psoriatic Arthritis Response Criteria (PsARC). Review Manager
4.2 software was applied for the analysis, using the number
needed to treat (NNT) and relative risk (RR) as statistical
variables. Due to lack of face-to-face evidence on biologicals, in-
direct comparison was conducted applying Butcher’s method.
RESULTS: Six RCTs were identiﬁed involving altogether 982
patients on the active treatment arms: adalimumab (n = 413),
etanercept (n = 265) and inﬂiximab (n = 304). All trials were
placebo controlled, the primary follow-up time was 12–16 weeks
and the primary outcome was ACR20. The NNTs (95% conﬁ-
dence intervals) for adalimumab, etanercept and inﬂiximab were
2.6 (2.1–3.2), 2.1 (1.7–2.7) and 2.0 (1.7–2.4) patients to achieve
ACR20 outcome and 2.9 (2.3–4.0), 2.2 (1.8–2.8) and 2.0
(1.6–2.4) to fulﬁll PsARC outcome, respectively. Indirect pair-
wise comparisons of TNF-alpha inhibitors yielded the RR of
0.87 (0.50–1.51) for adalimumab vs. etanercept, of 1.37 (0.72–
2.61) for inﬂiximab vs. etanercept and of 1.57 (0.87–2.86) for
inﬂiximab vs. adalimumab. CONCLUSION: Adalimumab, etan-
ercept and inﬂiximab are effective for the treatment of PsA. Both
the NNTs and the responsiveness of the three drugs at PsARC
and ACR20 outcomes are similar. Indirect comparison did not
reveal signiﬁcant difference in the efﬁcacy among the TNF-alpha
inhibitors in PsA.
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OBJECTIVE: To compare the efﬁcacy of etoricoxib, lumira-
coxib, celecoxib, non-selective (ns) NSAIDs and acetaminophen
in the treatment of osteoarthritis. METHODS: RCTs investigat-
ing the effects of acetaminophen 4000 mg, diclofenac 150 mg,
naproxen 1000 mg, ibuprofen 2400 mg, celecoxib 100–400 mg,
lumiracoxib 100–400 mg, and etoricoxib 60 mg with a treat-
ment duration of at least two weeks were identiﬁed with a
systematic literature search. Endpoints of interest were pain,
physical function and patient global assessment of disease status
(PGADS). Pain and physical function reported on VAS or
LIKERT scales were translated into effect sizes (ES). PGADS was
reported on a 0–100 mm VAS scale. An ES 0.2–0.5 was deﬁned
as a “small” treatment effect, whereas ES of 0.5–0.8 and >0.8were
deﬁned as “moderate” and “large”, respectively. Outcomes of all
trials were analyzed simultaneously with a Bayesian mixed treat-
ment comparison. A negative estimate indicates favourable out-
comes. RESULTS: There is an 84% probability that etoricoxib
60 mg shows the greatest improvement in pain of all interventions
compared, followed by diclofenac 150 mg (7% probability) and
ibuprofen 2400 mg (4%). Etoricoxib 60 mg showed an ES of
-0.62 (95%Credible Interval -0.78; -0.45) relative to placebo, an
ES of -0.12 (-0.33; 0.07) relative to diclofenac 150 mg, and an ES
of -0.21 (-0.50; 0.07) relative to ibuprofen. Regarding physical
functioning, there is an 85% probability that etoricoxib 60 mg
showed the greatest improvement, followed by diclofenac 150 mg
(8% probability) and ibuprofen 2400 mg (4%). ESs of etoricoxib
60 mg relative to diclofenac 150 mg and ibuprofen 2400 mgwere
-0.12 (-0.34; 0.08), and -0.23 (-0.53; 0.06) respectively. The
greatest improvements regarding PGADS were expected with
diclofenac (29% probability) followed by etoricoxib (25%).
CONCLUSION: The current study estimated the efﬁcacy of
acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA
and demonstrated that etoricoxib 60 mg is likely to result in the
greatest improvements in pain and physical function.
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OBJECTIVE: The aim of our study was to examine the relation-
ship between volume (annual number of patients) and outcome
(30 days mortality) in patients with femoral neck fracture.
METHODS: Data derived from the nationwide dataset of the
National Health Insurance Fund Administration. Patients aged
over 60 years with femoral neck fracture admitted to acute care
hospital were included into the study. 30 days mortality follow-
ing the primary surgical treatment was analyzed. We examined
the relationship between volume (annual number of patients) and
outcome (30 days mortality). First quintiles with similar patient
number was applied (method I), than the patient number itself
was the variable (method II). Several other covariates were
included into the analysis: sex, age, co-morbidities, type and
location of fracture, type of surgery (ostheosynthesis, arthro-
plasty), within 30 days complications, hospital type, day of
surgery and surgical delay. The association between covariates
was evaluated with logistic regression analysis (OR: odds ratio,
95% CI: conﬁdence interval, p value). RESULTS: Altogether
3783 patient from 65 different hospitals were included into the
study. The average 30 days mortality was 8.99 %, ranging
between 7.82–10.0 % (method I). Using the volume data itself as
continuous variable (method II), the connection between volume
and outcome could not be proven (ORunivariate = 0.998,
CI: 0.9974–1.0005, p: 0.1779; ORmultivariate = 0.9987, CI:
0.9962–1.0013, p: 0.3378). We did not ﬁnd any relationship
between hospital volume and outcome in patients with femoral
neck fracture. However it is important to highlight the role of
hospital type, where treatment at medical university (medical
school) is associated with signiﬁcantly lower 30 days mortality.
CONCLUSION: We would like to emphasize on the analysis of
our nationwide dataset that initial treatment in high-volume
hospitals was not associated with lower 30 days mortality.
However, type of hospital (teaching status) seems to be more
important predictor of 30 days mortality.
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OBJECTIVE: To understand the impact of the October 2004
withdrawal of rofecoxib on prescription analgesic use for arthri-
tis patients who had been taking this medication. METHODS:
Patients were selected from the MarketScan databases who,
during January-September 2004, had a diagnosis of osteoarthri-
tis on a medical claim and who ﬁlled prescriptions for at least 90
days of therapy with rofecoxib, an alternative COX-2 inhibitor
(celecoxib), or a branded, non-selective, nonsteroidal, anti-
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